Skip to main content

Advertisement

Table 1 Baseline characteristics of the study population

From: Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial

Variables CYC (n = 21) MMF (n = 21) P-value
Age (years) 24.67 ± 11.66 27.24 ± 9.34 0.435
Gender, n (%)
 Female 19 (90.5) 18 (85.7) 1.000
 Male 2 (9.5) 3 (14.3)  
Body Mass Index (kg/m2) 19.64 ± 3.00 21.00 ± 3.08 0.154
BSA (m2) 1.48 ± 0.14 1.44 ± 1.38 0.404
SLEDAI Score 16.21 ± 4.32 15.92 ± 3.45 0.653
SLICC Criteria 11.23 ± 2.34 10.56 ± 4.78 0.562
eGFR Range (ml/min/1.73m2), n (%)
  ≥ 90 3 (14.3) 6 (28.6) 0.381
 60–89 10 (47.6) 6 (28.6)  
  ≤ 59 8 (38.1) 9 (42.9)  
Renal biopsy class, n (%)
 Class III/III + V 5 (23.8) 4 (19.0) 0.143
 Class IV/IV + V 16 (76.2) 13 (62)  
 Class V 0 4 (19.0)  
Activity index (AI) 8.09 ± 4.55 8.23 ± 3.22 2.342
Chronicity index (CI) 1.76 ± 1.72 2.61 ± 1.68 1.453
Crescents, n (%) 4 (19.04) 2 (9.52) 0.092
Serum urea (mg/dL) 62.86 ± 56.62 46.05 ± 38.05 0.266
Serum creatinine (mg/dL) 1.73 ± 1.72 1.24 ± 0.53 0.223
Positive anti-dsDNA, n (%) 17 (81.0) 19 (90.5) 0.663
Serum albumin (gm/dL) 2.75 ± 0.65 2.98 ± 0.67 0.266
Urinary 24-h protein excretion (gm) 3.32 ± 3.53 3.30 ± 2.42 0.993
  1. SLEDAI Systemic Lupus Erythematosus Disease Activity Index, SLICC Systemic Lupus International Collaborative Clinic